Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) EPS (Weighted Average and Diluted) (2024 - 2025)

Caris Life Sciences has reported EPS (Weighted Average and Diluted) over the past 2 years, most recently at $1.61 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $1.61 for Q4 2025, up 192.53% from a year ago — trailing twelve months through Dec 2025 was -$8.02 (changed N/A YoY), and the annual figure for FY2025 was -$3.22, up 69.79%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $1.61 at Caris Life Sciences, up from $0.08 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CAI hit a ceiling of $1.61 in Q4 2025 and a floor of -$7.97 in Q2 2025.